Curdin Conrad, Christine-Elke Ortmann, Marc Vandemeulebroecke, Torben Kasparek, Kristian Reich
Issues - Febbraio 2022
Curdin Conrad, Christine-Elke Ortmann, Marc Vandemeulebroecke, Torben Kasparek, Kristian Reich
Linda Stein Gold, Kim Papp, David Pariser, Lawrence Green, Neal Bhatia, Howard Sofen, Lorne Albrecht, Melinda Gooderham, Mindy Chen, Maria Paris, Yao Wang, Kristina Callis Duffin
Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial
J Am Acad Dermatol. 2022 Jan;86(1):77-85James G Krueger, Iain B McInnes, Andrew Blauvelt
Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis
J Am Acad Dermatol. 2022 Jan;86(1):148-157A Pinter, L J Green, J Selmer, M Praestegaard, L S Gold, M Augustin, trial investigator group
A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis
J Eur Acad Dermatol Venereol. 2022 Feb;36(2):228-236K Hansel, A Zangrilli, L Bianchi, K Peris, A Chiricozzi, A Offidani, F Diotallevi, M C Fargnoli, M Esposito, P Amerio, G Gualdi, L Bianchi, L Stingeni
A 52-week update of a multicentre real-life experience on effectiveness and safety of risankizumab in psoriasis
J Eur Acad Dermatol Venereol. 2022 Feb;36(2):e111-e113Deepak M W Balak, Stefano Piaserico, Ismail Kasujee
Non-Alcoholic Fatty Liver Disease (NAFLD) in Patients with Psoriasis: A Review of the Hepatic Effects of Systemic Therapies
Psoriasis (Auckl). 2021 Dec 7;11:151-168A Al-Janabi, Z Z N Yiu
Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management
Psoriasis (Auckl). 2022 Jan 6;12:1-14D Thaçi, K Eyerich, A Pinter, M Sebastian, K Unnebrink, S Rubant, D A Williams, P Weisenseel
Direct comparison of risankizumab and fumaric acid esters in systemic therapy-naïve patients with moderate-to-severe plaque psoriasis: a randomized controlled trial
Br J Dermatol. 2022 Jan;186(1):30-39Mark Lebwohl, Richard G Langley, Carle Paul, Lluis Puíg, Kristian Reich, Peter van de Kerkhof, Hsiuan-Lin Wu, Sven Richter, Shauna Jardon, Paolo Gisondi
Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey
Dermatol Ther (Heidelb). 2022 Jan;12(1):61-78Shinichi Imafuku, Yayoi Tada, Yoshinori Umezawa, Shinya Sakurai, Naoki Hoshii, Hidemi Nakagawa
Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: Effect of Demographics and Baseline Disease Characteristics on Efficacy
Dermatol Ther (Heidelb). 2022 Jan;12(1):121-135Y Lytvyn, J R Georgakopoulos, A Mufti, A R Devani, M J Gooderham, V Jain, P Lansang, R Vender, V H Prajapati, J Yeung